Biofrontera Inc. Proceeds from Issuance or Sale of Equity
Biofrontera Inc. (BFRI) reported Proceeds from Issuance or Sale of Equity of $7.66 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOrSaleOfEquity · last filed 2026-03-19
- Biofrontera Inc. proceeds from issuance or sale of equity for the quarter ending 2024-12-31 was $0.00.
- Biofrontera Inc. proceeds from issuance or sale of equity for the quarter ending 2024-09-30 was $0.00.
- Biofrontera Inc. proceeds from issuance or sale of equity for the quarter ending 2024-06-30 was $0.00.
- Biofrontera Inc. proceeds from issuance or sale of equity for the quarter ending 2024-03-31 was $7.66M.
- Biofrontera Inc. proceeds from issuance or sale of equity for fiscal 2024 was $7.66M, a 70.00% increase from fiscal 2023.
- Biofrontera Inc. proceeds from issuance or sale of equity for fiscal 2023 was $4.51M, a 52.01% decline from fiscal 2022.
- Biofrontera Inc. proceeds from issuance or sale of equity for fiscal 2022 was $9.39M.
| Period end | Proceeds from Issuance or Sale of Equity 3 month | Proceeds from Issuance or Sale of Equity 6 month | Proceeds from Issuance or Sale of Equity 9 month | Proceeds from Issuance or Sale of Equity 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $0.00 derived: sum of 3 quarters · filed 2026-03-19 | $7.66M 10-K · filed 2026-03-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $7.66M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $7.66M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | $7.66M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $4.51M 10-K · filed 2024-03-15 | |||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $0.00 derived: sum of 2 quarters · filed 2024-03-15 | $9.39M 10-K · filed 2024-03-15 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $9.39M 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $9.39M 10-Q · filed 2023-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |